Kong Yiu Cheung Purchases 500,000 Shares of NewGenIvf Group (NASDAQ:NIVF) Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 500,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was acquired at an average cost of $1.33 per share, with a total value of $665,000.00. Following the purchase, the director directly owned 722,223 shares in the company, valued at $960,556.59. This represents a 225.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung acquired 2,500,000 shares of NewGenIvf Group stock. The stock was purchased at an average price of $1.00 per share, for a total transaction of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock. The shares were bought at an average cost of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Stock Down 1.4%

Shares of NIVF stock opened at $1.33 on Wednesday. The company has a quick ratio of 2.98, a current ratio of 3.12 and a debt-to-equity ratio of 0.16. The business’s fifty day moving average is $2.96 and its 200 day moving average is $11.34. NewGenIvf Group Limited has a twelve month low of $1.15 and a twelve month high of $1,539.00.

Analysts Set New Price Targets

NIVF has been the subject of a number of analyst reports. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.